top of page

Recent Posts

Search

FDA Approves Rare Pediatric Disease Designation for IMX-110 for Rhabdomyosarcoma

OPACC
Jan 19, 2022
1 min read

Officials with the FDA have approved a Rare Pediatric Disease Designation for IMX-110 for the treatment of pediatric patients with rhabdomyosarcoma.

Read more: https://www.pharmacytimes.com/view/fda-approves-rare-pediatric-disease-designation-for-imx-110-for-rhabdomyosarcoma

Recent Posts

Auditory Attention Decay Noted Post-Treatment in Pediatric Cerebellar Tumors

Quality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric...

Cardiometabolic Considerations for Childhood Cancer Survivors Explained

A team of experts, issuing a statement on behalf of the American Heart Association, have detailed cardiometabolic considerations for...

Sex and Age May Influence Comorbidities in Pediatric ALL

While the overall prevalence of comorbidities at diagnosis in pediatric patients with acute lymphoblastic leukemia (ALL) and...

Comments

Auditory Attention Decay Noted Post-Treatment in Pediatric Cerebellar Tumors

Cardiometabolic Considerations for Childhood Cancer Survivors Explained

Sex and Age May Influence Comorbidities in Pediatric ALL

FDA Grants Rare Pediatric Designation to Treatment With NEO100 in Brain Cancer

Untreated GHD Linked to Adverse Outcomes in Childhood Cancer Survivors

Trial Shows Targeted Treatment for Childhood Brain Tumor is Safe

New approach speeds up personalized cancer treatment for young patients

Motor Deficits in Children Off Therapy for Acute Lymphoblastic Leukemia

Boys with cancer can face infertility as adults. Can storing their stem cells help?

HRD HSCT Shows Promise Among Pediatric Patients With Hematologic Cancers

Archive

Search By Tags

bottom of page